![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With Psychiatric Disorders
|
|
|
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
David Back1, Pamela Belperio2, Mark Bondin3, Francesco Negro4, Andrew H Talal5, Caroline Park3, Yang Lei3, Brett Pinksy3, Eric Crown3, Federico Mensa3, Fiona Marra1
1University of Liverpool, Liverpool, United Kingdom; 2US Department of Veterans Affairs, VA Palo Alto Healthcare System, Palo Alto, California, United States; 3AbbVie Inc., North Chicago, Illinois, United States;
4University of Geneva, Geneva, Switzerland; 5Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, New York, United States
![0413181](../images%20/041318/041318-1/0413181.gif)
![0413182](../images%20/041318/041318-1/0413182.gif)
![0413183](../images%20/041318/041318-1/0413183.gif)
![0413184](../images%20/041318/041318-1/0413184.gif)
![0413185](../images%20/041318/041318-1/0413185.gif)
![0413186](../images%20/041318/041318-1/0413186.gif)
![0413187](../images%20/041318/041318-1/0413187.gif)
![0413188](../images%20/041318/041318-1/0413188.gif)
![0413189](../images%20/041318/041318-1/0413189.gif)
![04131810](../images%20/041318/041318-1/04131810.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|